Abstract：Objective To explore the effect of Rosuvastatin combined with Ezetimibe in patients with myocardial infarction and its influence on the level of inflammatory factors.Methods A total of 94 patients with myocardial infarction admitted to the Third People′s Hospital of Dalian from January 2019 to January 2020 were selected as the research subjects and divided into the study group(47 cases)and the control group(47 cases)according to the random number table method.The control group was treated with Rosuvastatin,and the study group was treated with Rosuvastatin combined with Ezetimibe.The inflammatory factor levels(tumor necrosis factor -α[TNF-α],hypersensitive C-reactive protein[hs-CRP]and interleukin 6[IL-6]),treatment effect and blood lipid levels(total cholesterol[TC],triylglycerol[TG],low density lipoprotein cholesterol[LDL-C]),the total incidence of adverse reactions and myocardial enzyme levels(lactate dehydrogenase[LDH],creatine kinase[CK],creatinine kinase isoenzyme[CK-MB])of two groups were compared.Results The levels of TNF-α,hs-CRP and IL-6 in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).The total effective rate of the study group was higher than that of the control group,and the difference was statistically significant(P<0.05).Before the treatment,there were no statistically significant differences in the levels of TC,TG,LDL-C between the two groups(P>0.05).After the treatment,the levels of TC,TG,LDL-C in the study group were lower than those in the control group,with statistically significant difference(P<0.05).The total incidence of adverse reactions in the study group was lower than that in the control group,and the difference was statistically significant(P<0.05).Before the treatment,there were no statistically significant differences in the levels of LDH,CK and CK-MB between the two groups(P>0.05).After the treatment,the levels of LDH,CK and CK-MB in the study group were lower than those in the control group,with statistically significant difference(P<0.05).Conclusion Patients with myocardial infarction were treated with Rosuvastatin combined with Ezetimibe,with a certain therapeutic effect,could effectively improve the clinical symptoms in patients with myocardial infarction,at the same time,also can effectively reduce the blood lipid levels in patients with myocardial infarction,inhibiting inflammatory reaction,reduce the adverse reaction condition,high safety,it′s worth popularizing further application in clinic.
Olga Krystufková，Hulejová Hana，Mann HF，et al.Serum levels of B－cell activating factor of the TNF family（BAFF）correlate with anti－Jo－1 autoantibodies levels and disease activity in patients with anti－Jo－1positive polymyositis and dermatomyositis[J].Arthritis Res Ther，2018，20（1）：158．
Benekos T，Kosmeri C，Vlahos A，et al.Nine－year overview of dyslipidemia management in children with heterozygous familial hypercholesterolemia：a university hospital outpatient lipid clinic project in Northwestern Greece[J].J.Pediatr.Endocrinol.Metab，2020，33（4）：533－538．
Lin CY，Hwang YT，Chen PC，et al.Association of serum levels of 4－tertiary－octylphenol with cardiovascular risk factors and carotid intima－media thickness in adolescents and young adults[J].Environ.Pollut，2019，246（5）：107－113．
Hong SJ，Jeong HS，Ahn JC，et al.A Phase Ⅲ，Multicenter，Randomized，Double－blind，Active Comparator Clinical Trial to Compare the Efficacy and Safety of Combination Therapy With Ezetimibe and Rosuvastatin Versus Rosuvastatin Monotherapy in Patients With Hypercholesterolemia： IROSETTE（Ildong Rosuvastatin &Ezetimibe for Hypercholesterolemia）Randomized Controlled Trial[J].Clin Ther，2018，40（2）：226－241．
[15]
Rhee MY，Kim KJ，Kim SH，et al.Ezetimibe and Rosuvastatin Combination Treatment Can Reduce the Dose of Rosuvastatin Without Compromising Its Lipid－lowering Efficacy[J].C Clin Ther，2019，41（12）：2571－2592．
京公网安备 11010502046607号